S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
66,000% upside on tiny biotech? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
66,000% upside on tiny biotech? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
66,000% upside on tiny biotech? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
66,000% upside on tiny biotech? (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
66,000% upside on tiny biotech? (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Forecast, Price & News

$31.64
-0.29 (-0.91%)
(As of 09/22/2023 ET)
Compare
Today's Range
$31.55
$32.42
50-Day Range
$22.94
$33.80
52-Week Range
$17.86
$34.28
Volume
619,161 shs
Average Volume
559,125 shs
Market Capitalization
$3.24 billion
P/E Ratio
38.12
Dividend Yield
N/A
Price Target
$30.81

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
2.6% Downside
$30.81 Price Target
Short Interest
Bearish
16.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.33mentions of Corcept Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$2.75 M Sold Last Quarter
Proj. Earnings Growth
6.41%
From $0.78 to $0.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

721st out of 963 stocks

Pharmaceutical Preparations Industry

332nd out of 455 stocks


CORT stock logo

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Price History

CORT Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Massive Insider Trade At Corcept Therapeutics
Unusual Passive Income Investment (Found on a Golf Course)
One man turned $1,000 into a decades long passive income stream... eventually reaching $100,000 per year! All from a single golf course tip. CLICK HERE TO FIND OUT HOW HE DID IT
Why Is Corcept (CORT) Up 4.8% Since Last Earnings Report?
Expert Ratings for Corcept Therapeutics
Will Corcept (CORT) Gain on Rising Earnings Estimates?
Why Corcept Therapeutics Stock Popped Today
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
299
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$30.81
High Stock Price Forecast
$47.50
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
-2.6%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$101.42 million
Pretax Margin
25.38%

Debt

Sales & Book Value

Annual Sales
$401.86 million
Cash Flow
$0.97 per share
Book Value
$4.66 per share

Miscellaneous

Free Float
82,243,000
Market Cap
$3.24 billion
Optionable
Optionable
Beta
0.45

Social Links

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Joseph K. Belanoff M.D. (Age 66)
    Co-Founder, Pres, CEO & Director
    Comp: $1.82M
  • Mr. Atabak Mokari (Age 46)
    CFO & Treasurer
    Comp: $760.75k
  • Dr. Hazel Hunt Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $895.16k
  • Mr. Sean MaduckMr. Sean Maduck (Age 46)
    Pres of Corcept Endocrinology
    Comp: $823.42k
  • Mr. Gary Charles Robb (Age 60)
    Chief Bus. Officer & Sec.
    Comp: $963k
  • Mr. Joseph Douglas LyonMr. Joseph Douglas Lyon (Age 44)
    Chief Accounting Officer
  • Ms. Amy Flood
    Chief HR & Communications Officer
  • Dr. William Guyer Pharm.D. (Age 55)
    Chief Devel. Officer













CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CORT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CORT, but not buy additional shares or sell existing shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 1-year target prices for Corcept Therapeutics' stock. Their CORT share price forecasts range from $22.00 to $47.50. On average, they expect the company's share price to reach $30.81 in the next twelve months. This suggests that the stock has a possible downside of 2.6%.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2023?

Corcept Therapeutics' stock was trading at $20.31 at the beginning of 2023. Since then, CORT shares have increased by 55.8% and is now trading at $31.64.
View the best growth stocks for 2023 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. The biotechnology company earned $117.72 million during the quarter, compared to analyst estimates of $109.60 million. Corcept Therapeutics had a net margin of 22.02% and a trailing twelve-month return on equity of 19.57%. The business's quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.24 earnings per share.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.00 million-$470.00 million, compared to the consensus revenue estimate of $443.89 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.91%), Ingalls & Snyder LLC (8.23%), Renaissance Technologies LLC (6.53%), Parallel Advisors LLC (3.67%), State Street Corp (3.09%) and Dimensional Fund Advisors LP (2.20%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $31.64.

How much money does Corcept Therapeutics make?

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $3.24 billion and generates $401.86 million in revenue each year. The biotechnology company earns $101.42 million in net income (profit) each year or $0.83 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

The company employs 299 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -